Eisai is launching a special dementia discovery centre to boost development of next-generation medicines targeting forms of the condition, including Alzheimer’s disease.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh